top of page
  • Facebook
  • Twitter
  • LinkedIn
  • Instagram

BARDA DxR2 Funding Opportunity: Develop and Deploy Biothreat Diognostics

  • Tyler Maxwell
  • Jun 27
  • 2 min read

The Biomedical Advanced Research and Development Authority (BARDA) is investing in the next generation of point-of-care (POC) biothreat diagnostics through the DxR2 (Diagnostic Rapid Response) initiative. This OTA-funded opportunity supports the design, validation, and manufacturing transfer of diagnostic tests targeting high-priority biological threats.


This is a compelling opportunity for diagnostic companies to partner with BARDA and advance technologies critical to public health preparedness.


Solicitation Overview

  • Opportunity Name: Biothreat Diagnostic Rapid Response (DxR2)

  • Solicitation Number: RRPV-25-06-DxR2

  • Issuing Agency: BARDA, via the Rapid Response Partnership Vehicle (RRPV)

  • Contracting Mechanism: Other Transaction Agreement (OTA)

  • Total Available Funding: $40M

  • Base Period Duration: 36 Months

  • Proposal Due Date: August 4, 2025 @ 1:00 PM ET


Proposal Requirements

Offerors must submit the following documents using BARDA provided templates:

  1. Technical Proposal (30-page limit + required attachments)

  2. Cost Proposal (narrative and Excel cost breakdown)

  3. Statement of Work / Milestone Payment Schedule


Program Phases & Strategic Goals

Base Period (Required)

  • Develop diagnostics for one or more of the following: Glanders, Botulism toxxin (BoNT), Tularemia, Typhus, Smallpox, Plague

  • Execute FDA clearance strategy and transfer to U.S. manufacturing

  • Complete kit and sample stability studies and capacity assessments

Option Period I

  • Maintain warm-base surge capacity

  • Manufacture kits for stockpiling, training, and emergency use

Option Period II

  • Implement just-in-time manufacturing upgrades

  • Enable rapid scale-up and deployment for public health emergencies


How Rosewater Consulting Can Help

At Rosewater Consulting, we specialize in helping diagnostic and life science companies secure government funding through OTA and R&D-focused solicitations. We offer:

  • End-to-end proposal strategy and compliance

  • Technical narrative support and cost structure modeling

  • Project management planning and milestone development

Contact us today to see if your diagnostic platform is a fit for DxR2. Together, we'll build a winning approach.


ree


bottom of page